Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosiglitazone.

B H Wolffenbuttel1, J P Sels, M S Huijberts

  • 1Dept. of Endocrinology & Metabolism, University Hospital Maastricht, P.O. Box 5800, NL-6202 AZ Maastricht, The Netherlands. bwo@sint.azm.nl

Expert Opinion on Pharmacotherapy
|May 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

A survey of natural protein intake in Dutch phenylketonuria patients: insight into estimation or measurement of dietary intake.

Journal of the American Dietetic Association·2008
Same author

From shared care to disease management: key-influencing factors.

International journal of integrated care·2006
Same author

[Empty sella syndrome as the cause of panhypopituitarism].

Nederlands tijdschrift voor geneeskunde·2004
Same author

Clinical experience with Sandostatin LAR in patients with acromegaly.

The Netherlands journal of medicine·2001
Same author

Substitution model with central role for nurse specialist is justified in the care for stable type 2 diabetic outpatients.

Journal of advanced nursing·2001
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Rosiglitazone, an insulin sensitizer, effectively lowers blood glucose in Type 2 diabetes patients. While generally safe, further research is needed on its long-term effects and combination therapy with insulin.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus involves impaired insulin secretion, reduced peripheral insulin action, and increased hepatic glucose production.
  • Near-normal glucose control may mitigate microvascular and macrovascular complications in Type 2 diabetes.
  • Thiazolidinediones, like rosiglitazone, enhance insulin sensitivity by activating the PPARgamma nuclear receptor.

Purpose of the Study:

  • To evaluate the efficacy and safety of rosiglitazone in managing Type 2 diabetes mellitus.
  • To assess rosiglitazone's impact on glycemic control in patients on various therapeutic regimens.
  • To explore potential benefits beyond glycemic control and identify safety concerns.

Main Methods:

  • Clinical studies involving Type 2 diabetic patients treated with diet, sulfonylurea, metformin, or insulin.

Related Experiment Videos

  • Assessment of HbA1c levels as a primary efficacy endpoint.
  • Monitoring for side effects, including hypoglycemia, gastrointestinal issues, fluid retention, and hepatotoxicity.

    • Main Results:

    • Rosiglitazone effectively reduced HbA1c levels by 0.5-1.5% in diet-treated patients and 1.0-1.2% when added to sulfonylurea therapy.
    • Preliminary data suggest glycemic improvement and a slight decrease in insulin dosage in insulin-treated patients.
    • Rosiglitazone did not cause hypoglycemia or gastrointestinal side effects; fluid retention is a noted concern.

    Conclusions:

    • Rosiglitazone is an effective insulin sensitizer for Type 2 diabetes, offering moderate glycemic control improvements.
    • Further investigation is required to determine the clinical relevance of potential benefits on blood pressure and microalbuminuria.
    • Long-term studies are needed to assess beta-cell function preservation, diabetes-related complications, and atherosclerosis reduction, especially in combination with insulin therapy.